pharmaphorum

APRIL 29, 2022

An artificial intelligence-powered digital tool for diagnosing skin cancers developed by Skin Analytics has been cleared in the UK as a Class IIA medical device, setting up broader use of the technology in patient assessments. DERM is being deployed in pilot studies across five NHS Trusts, for example to see if it can support GPs in referring patients to the urgent two week skin cancer referral laid out in NICE guidelines.

Hospitals 145

Hospitals 145

Pharma Times

APRIL 28, 2022

Women, those who are obese and those on mechanical ventilation are all more likely to suffer from the effects long-term COVID-19

142

142

Drug Patent Watch

APRIL 26, 2022

Annual Drug Patent Expirations for INVEGA+TRINZA Invega Trinza is a drug marketed by Janssen Pharms and is included in one NDA. It is available from one supplier. There is one…. The post New patent for Janssen Pharms drug INVEGA TRINZA appeared first on DrugPatentWatch - Make Better Decisions.

98

98

Drug Channels

APRIL 26, 2022

Baseball season is in full swing! Oil up your glove, lace up your cleats, and let's run the bases around this month's news stories. Remember: Sometimes you win, sometimes you lose, and sometimes it rains. In this issue: Green Monster : The 340B market hits new highs in 2021 Not-Free Agents : Big 340B profits for CVS, Walgreens, Express Scripts, et al Batter Up : Fixing the insulin market Pinch Hitters : Walgreens bets on robots Plus, Dr.

Specialty Pharmacies 81

Specialty Pharmacies 81

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

APRIL 25, 2022

An analysis of 10 clinical trials of digital health interventions targeted at patients recently hospitalised for acute heart failure has found they improve outcomes compared to standard care. The meta-analysis by researchers in the US pooled the results of the studies to assess the impact of digital approaches like telemedicine, use of monitoring sensors, Internet-based interventions, smartphone apps, or text messaging/email interactions on all-cause mortality.

Hospitals 134

Hospitals 134

Pharma Times

APRIL 29, 2022

NICE urges older people to stop routine painkiller use – over 10 million in the UK suffer a form of arthritis or other joint conditions

114

114

Outsourcing Pharma

APRIL 26, 2022

The companyâs Precision Olfactory Delivery technology, currently combined with its Trudhesa migraine treatment, reportedly facilitates high absorption rates.

84

84

pharmaphorum

APRIL 27, 2022

As the landscape of healthcare changes, so too must the way that we interpret and measure performance and success. This is particularly evident in marketing. Before the COVID-19 pandemic, measuring engagement typically involved detailed follow-ups, contacting a pool of practitioners to gauge their awareness of a particular product and then extrapolating that information across the country.

Hospitals 113

Hospitals Communication 113

Pharma Times

APRIL 25, 2022

Studies have demonstrated that Healome’s formulations have anti-fibrotic activity and are augmented when combined with other therapeutics

109

109

Drug Channels

APRIL 29, 2022

Today’s guest post comes from Chris Harvey, Director of Solutions Engineering at Panalgo, and Carolyn Zele, Senior Manager of Solution Enablement at MMIT. Chris and Carolyn discuss the insights that health economics and outcomes research (HEOR) professionals bring to commercial teams. They explain how that pairing benefits both manufacturers and patients.

75

75

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

NY Times

APRIL 28, 2022

Both antiviral treatments and monoclonal antibodies that treat Covid-19 are available across the city, but some public health experts worry that too few people know how to get them.

64

64

pharmaphorum

APRIL 29, 2022

AstraZeneca has revealed plans to set up a new strategic R&D hub in Cambridge, Massachusetts as it reported a massive increase in first-quarter revenues, driven by COVID-19 and oncology drugs and heart failure therapy Farxiga. The new site will be at Kendall Square and will serve as the new corporate headquarters for Alexion – which is currently based across the Charles River in Boston’s Seaport District – as well as housing around 1,500 R&D staff from AZ and Alexion in a new purpo

Diabetes 107

Diabetes Vaccines 107

Pharma Times

APRIL 26, 2022

Follow-on collaboration between ViGeneron and Daiichi Sankyo allows the companies to create and validate vgAAV-based therapeutic candidates

106

106

Drug Channels

APRIL 25, 2022

Informa Connect’s Patient Support Services Congress. Hybrid Event | June 14-16 in Philadelphia, PA www.informaconnect.com/patientsupport. Exclusive Offer – Be sure to use your exclusive promo PSS22DC to save 10% off* of your registration. A proven industry staple, Patient Support Services Congress is back June 14-16, 2022 and ready to arm industry with next-generation approaches to patient services for optimal program performance.

Communication 64

Communication 64

NY Times

APRIL 26, 2022

Moderna and the Pfizer-BioNTech partnership are developing versions of their coronavirus vaccines for children under 5, with emergency-use filings expected in the next several weeks.

Vaccines 58

Vaccines Immunity Immunization 58

pharmaphorum

APRIL 26, 2022

Compared to a ‘critical organ’ that had been largely ignored, companies working to develop microbiome-based therapies believe there is untapped potential in the area. Ben Hargreaves speaks to companies that are developing therapies not just in gastrointestinal conditions but also in broader areas, such an immuno-oncology. The interest in how the human microbiome influences health has grown substantially in the last decade.

Immunity 104

Immunity Immunization Diabetes Drug Development 104

Pharma Times

APRIL 26, 2022

The Foundation also launched a new collaboration with Diabetes UK and the Juvenile Diabetes Research Foundation UK

Diabetes 118

Diabetes 118

Drug Patent Watch

APRIL 29, 2022

Annual Drug Patent Expirations for EDURANT Edurant is a drug marketed by Janssen Prods and is included in one NDA. It is available from one supplier. There are four patents…. The post New patent for Janssen Prods drug EDURANT appeared first on DrugPatentWatch - Make Better Decisions.

52

52

NY Times

APRIL 27, 2022

The consulting firm’s top executive was apologetic before Congress but denied that advising both opioid manufacturers and their federal regulator posed a conflict of interest.

54

54

pharmaphorum

APRIL 28, 2022

Orders for Merck & Co’s oral antiviral for COVID-19 helped to swell the drugmaker’s first quarter revenues by a massive 50%, although underlying growth was also strong. Lagevrio (molnupiravir) added $3.2 billion to Merck’s top line of $15.9 billion, but even without the drug sales would have risen 19% thanks to a strong performance from cancer immunotherapy Keytruda (pembrolizumab) and the Gardasil human papillomavirus (HPV) vaccine range.

Vaccines 103

Vaccines 103

Pharma Times

APRIL 28, 2022

Long-acting hypertension treatment could provide patients with an injection of medication every six months

119

119

Drug Patent Watch

APRIL 29, 2022

Annual Drug Patent Expirations for EMPAVELI Empaveli is a drug marketed by Apellis Pharms and is included in one NDA. There are seven patents protecting this drug. This drug has…. The post New patent for Apellis Pharms drug EMPAVELI appeared first on DrugPatentWatch - Make Better Decisions.

52

52

NY Times

APRIL 27, 2022

Pills and suppositories that promise to balance the vaginal microbiome are lining drugstore shelves and online marketplaces. But are they backed by science?

58

58

pharmaphorum

APRIL 25, 2022

Aaron Gani, founder and CEO of BehaVR, and Krys Zaluski, director of business development, digital health at Sumitomo Dainippon Pharma, discuss their groundbreaking partnership to develop and commercialise digital therapeutics (DTx) products. . BehaVR and Sumitomo signed a potential $140 million deal to create virtual reality (VR) therapies to treat social anxiety disorder, generalised anxiety disorder, and major depressive disorder.

99

99

Pharma Times

APRIL 27, 2022

MMM is a global campaign which raises awareness of high blood pressure and its long-term implications

115

115

Drug Patent Watch

APRIL 29, 2022

Annual Drug Patent Expirations for VUITY Vuity is a drug marketed by Abbvie Inc and is included in one NDA. It is available from one supplier. There is one patent…. The post New patent for Abbvie Inc drug VUITY appeared first on DrugPatentWatch - Make Better Decisions.

52

52

Flip the Pharmacy

APRIL 29, 2022

Aimee O’Reilly, RPh, PharmD Owner, O’Reilly Family Pharmacy Med sync has been a major focus of our pharmacy’s Flip the Pharmacy efforts. We work with patients to line up their medication to all be filled on one date and often talk about how this is much more convenient for them and makes it more likely that they remember to take their medications as prescribed.

Packaging 52

Packaging Hospitals 52

pharmaphorum

APRIL 29, 2022

For many patients with type 2 diabetes, having to inject basal insulin every day is a burdensome fact of life, but Novo Nordisk is trying to change that. The Danish drugmaker has reported the first phase 3 results with its new basal insulin product – insulin icodec – which backs up earlier data suggesting it could provide effective blood glucose control when injected just once a week.

Diabetes 98

Diabetes 98

Pharma Times

APRIL 29, 2022

InRange is the first worldwide multicentre RCT to compare second generation basal insulins

Diabetes 118

Diabetes 118

Fusion Pharmacy

APRIL 29, 2022

It is estimated that more than 50 million Americans are currently suffering from chronic pain due to a traumatic injury, a degenerative disease, a congenital condition, or simply from years of poor posture. Typically, pain medication is prescribed as the first line of treatment for chronic pain. However, many of these medications have specific risky side effects – ranging from nausea and drowsiness to heart complications.

Compounding 52

Compounding Specialty Pharmacies Dosage 52

The Honest Apothecary

APRIL 29, 2022

Focus is the secret to improvement in any area of your life and career. What you focus on, you will get better at. Whether it be art, or sports, or business, or any other area of interest…focus makes the difference between progress and plateau. When an organization, or an individual, loses their focus, they will slowly but surely decline. No focus = no progress.

52

52

pharmaphorum

APRIL 26, 2022

Biofourmis has raised $300 million in fourth-round financing, sending its value rocketing to around $1.3 billion and injecting some fresh momentum into the digital health sector after a slowdown in fundraising in the first quarter. The Boston-based startup – which has a business model straddling digital therapeutics (DTx), artificial intelligence-powered patient management and provision of virtual care – said the Series D will be used to fund clinical trials of its DTx candidates, scale up its v

Hospitals 98

Hospitals 98

Pharma Times

APRIL 25, 2022

Novartis will provide vital volunteering projects, career plans for young people and financial support to local charities

90

90

Drug Patent Watch

APRIL 28, 2022

Annual Drug Patent Expirations for CERDELGA Cerdelga is a drug marketed by Genzyme Corp and is included in one NDA. It is available from one supplier. There are six patents…. The post New patent expiration for Genzyme Corp drug CERDELGA appeared first on DrugPatentWatch - Make Better Decisions.

52

52

PharmaKinnex

APRIL 28, 2022

3 Reasons Why Rare Disease Marketing Strategies Need To Start With Inside Sales April 28, 2022. PharmaK. Over the past few years, rare disease drugs have seen an increase in research and development from the big pharmaceutical companies. Some of the many reasons for this are that rare disease drugs benefit from speedier clinical development timelines, lower commercialization costs, higher market valuation, and financial inflows for improving diagnosis and treatment approaches.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Communication Drug Development 52